Sunday, March 10, 2024 12:54:02 PM
- The Dexcom study used only participants that "had T1D, intensive insulin therapy T2D (T2D-IIT), or nonintensive insulin therapy T2D (T2D-NIIT)". Essentially, their study only involved Type 1 or Type 2 diabetics that were receiving treatment. The Know Labs MARD seems to include non-diabetics, pre-diabetics, Type 1 diabetics, and Type 2 diabetics. I would expect different MARD readings based on the population differences
- Most of the G7 MARD was based on normal usage across the 11 days that the device is working (the device has to be replaced on day 11). The MARD for the G7 was as high as 12.9% on the first day and tended to drop significantly by day 11 - the 8.2% MARD that they report is an average MARD across different days. The KNW MARD was based on readings after a glucose tolerance test. Again, you would expect different MARD readings as a result of different test protocols
I'm guessing that the testing that will be performed by KNW for FDA approval will be more rigorous and should provide results that can better compare to the performance reported for other devices on the market. In addition, the G7 device is the latest generation of Dexcom devices so you would hope that significant improvement has been made in the accuracy of the technology... the KnowU device is still undergoing development and should also continue to improve in accuracy. Finally, I don't think the KnowU needs to be the most accurate CGM device right out of the gate - if the accuracy is in the same ballpark then the cost and convenience benefits will probably be the biggest drivers of approval and adoption.
Recent KNW News
- Know Labs to Present Clinical Research at the 2024 American Physiology Summit • Business Wire • 04/05/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:10:40 PM
- Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study • Business Wire • 03/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:17:42 PM
- Know Labs Secures U.S. $12 Million Funding for Company’s Further Execution on Its Clinical Research and Development Initiatives • Business Wire • 02/29/2024 09:15:00 PM
- Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor • Business Wire • 02/27/2024 04:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 02:03:51 PM
- Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor • Business Wire • 02/27/2024 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:17:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:26 PM
- Know Labs, Inc. Reports First Quarter FY2024 Results • Business Wire • 02/14/2024 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:23:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:22:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:20:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:19:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:18:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:17:03 PM
- Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024 • Business Wire • 02/07/2024 02:00:00 PM
- Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) • Business Wire • 01/23/2024 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/12/2024 05:15:08 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/05/2024 09:16:39 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 09:15:52 PM
- Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 12/19/2023 09:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/19/2023 09:03:19 PM
FEATURED Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM